摘要
目的分析乳腺癌精准医疗的既往概况以及动态演化历程,探索未来乳腺癌的精准医疗研究的前沿热点和发展趋势。方法①以中国万方数据库和美国的Web of Science核心数据库关于乳腺癌精准医疗相关文献为信息来源,可视化分析相关文献的发表年份、国家、机构、作者、期刊、基金以及关键词分布,同时比较不同分子分型以及不同靶点乳腺癌研究的文献分布差异;②检索中国临床试验注册中心、北美临床试验注册中心、中国国家药品监督管理局以及美国食品药品监督管理局乳腺癌精准医疗的临床注册以及药物信息。结果①在中国共有450篇与乳腺癌精准医疗有关的研究文章,而在国际上有2303篇与乳腺癌精准治疗有关的研究文章,在中国以及全球均于2016年出现有关乳腺癌精准治疗研究文章的爆发式增长;Luminal A型、Luminal B型、HER2过表达型、基底细胞型(Basal-like型)以及三阴性乳腺癌中以三阴性乳腺癌精准医疗的研究文章数量最多,而乳腺癌精准治疗的主要靶点为HER2,EGFR,CDK4/6,PIK3CA和PARP,其中文献量最大的为HER2;②在全球范围内,美国的哈佛大学是发表乳腺癌精准治疗最多的机构,其次为法国国家健康与医学研究院,而后是加州大学以及德克萨斯大学,而中国发文机构的排名还不太高,仍有很大前进的空间;③美国是乳腺癌精准治疗研究的主要国家,发表超过900篇研究;④中国发文量最多的研究作者为解放军总医院第五医学中心(原解放军第307医院)乳腺肿瘤科的江泽飞教授,而在全球范围内发文量最多的是ANDRE F(巴黎第十一大学)和KATOH M(日本国立癌症研究中心);⑤《中华乳腺病杂志(电子版)》是中国发表乳腺癌精准治疗研究文章最多的期刊,全球发表乳腺癌精准治疗文章的主要期刊为《Personalized Medicine》;⑥全球范围中发表乳腺癌精准治疗研究文章的最主要资助机构
Objective To analyze the situation and dynamic evolution of precision medicine for breast cancer,and to explore the hotspots and development trends as well in the future.Methods①The studies concerning precision medicine for breast cancer were retrieved from the Wanfang database and Web of Science.Visualization technology was used to analyze publication year,country,institution,author,journal,fund,and keyword distribution of related studies.The distribution of the literatures on different molecular typing and different targets of breast cancer were compared.②Clinical registration,and drugs information of precision medicine for breast cancer were searched in Chinese Clinical Trial Register,ClinicalTrials.gov,China National Medical Products Administration and U.S.Food and Drug Administration.Results①There were 450 studies related to precision medicine for breast cancer published in China.While there were 2303 studies worldwide.The number of studies concerning on precision medicine for breast cancer in and outside China increased dramatically in 2016.Among the studies on Luminal A,Luminal B,HER2-overexpressing,Basal-like and triple-negative breast cancer,the number of studies on precision medicine for triple-negative breast cancer was the largest.The main targets of precision medicine for breast cancer contained HER2,EGFR,CDK4/6,PIK3CA and PARP.Of these targets,a majority of studies concerned on HER2.②The institution with the highest number of studies was Harvard University,followed by Institut National de la Sante et de la Recherche Medicale(French National Institute of Health and Medical Research),University of California,and University of Texas.The ranking of Chinese institutions was not high which can be improved greatly.③United States was the leading country for the study of precision medicine for breast cancer,with over 900 studies published.④The author with the highest number of studies in China was Professor Jiang Zefei from the Department of Breast Oncology,The Fifth Medical Center of PLA General
作者
张秀梅
翟运开
赵杰
赵萌
ZHANG Xiumei;ZHAI Yunkai;ZHAO Jie;ZHAO Meng(Institute of Scientific and Technical Information of China, Beijing 100038, China;WanFang Data Co., Ltd., Beijing 100038, China;School of Management Engineering, Zhengzhou University, Zhengzhou 450001, China;The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China)
出处
《中国肿瘤外科杂志》
CAS
2021年第1期25-32,共8页
Chinese Journal of Surgical Oncology
基金
国家重点研发计划“精准医学研究”重点专项(2017YFC0909900)。
关键词
精准医疗
个性化治疗
乳腺癌
大数据分析
可视化分析
Precision medicine
Personalized treatment
Breast cancer
Big data analysis
Visualized analysis
